North America RNA Therapeutics Market

North America RNA Therapeutics Market size was valued at USD 3.2 billion in 2025 and is forecast to grow from USD 3.7 billion in 2026 to reach USD 6.3 billion by 2031, at a CAGR of 14.6%.

Description

The North America RNA Therapeutics Market size was valued at USD 3.2 billion in 2025 and is forecast to grow from USD 3.7 billion in 2026 to reach USD 6.3 billion by 2031, at a CAGR of 14.6%. RNA therapeutics encompass messenger RNA, RNA interference, and antisense oligonucleotide-based drugs and vaccines that modulate gene expression or instruct cellular protein production, enabling targeted treatment approaches for oncology, infectious disease, and rare genetic disorders that were previously difficult to address with conventional small-molecule or biologic therapies. The market sits at the intersection of precision medicine, biopharmaceutical manufacturing, and gene-expression science, making it one of the most closely watched enabling technologies across the regional biotechnology and drug-development value chain.

Demand for RNA therapeutic platforms remains anchored by expanding oncology and rare-disease clinical pipelines, continued momentum from mRNA vaccine infrastructure built during recent years, and rising biopharmaceutical investment in RNA-based drug-delivery technologies across the United States, Canada, and Mexico. Beyond infectious-disease vaccines, RNA therapeutics continue to enable applications in gene silencing for cardiovascular and metabolic disease, personalized cancer immunotherapy, and rare genetic-disorder treatment that require precise, patient-specific molecular targeting. Rising biopharmaceutical R&D expenditure, expanding cold-chain and biomanufacturing infrastructure, and continued regulatory support for novel RNA-drug approvals are sustaining consumption even as the region transitions toward more diversified RNA-modality pipelines beyond vaccines.

Table of Contents

  • Product Overview

    1. Market Definition

    2. Scope of the Market

      1. Markets Covered

      2. Years Considered for Study

      3. Key Market Segmentations

  • Research Methodology

    1. Objective of the Study

    2. Baseline Methodology

    3. Key Industry Partners

    4. Major Association and Secondary Sources

    5. Forecasting Methodology

    6. Data Triangulation & Validation

    7. Assumptions and Limitations

  • Executive Summary

    1. Overview of the Market

    2. Overview of Key Market Segmentations

    3. Overview of Key Market Players

    4. Overview of Key Regions/Countries

    5. Overview of Market Drivers, Challenges, Trends

  • Voice of Customer

  • North America RNA Therapeutics Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Type (mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides (ASO), Others)

      2. By Application (Oncology, Infectious Diseases, Rare Genetic Disorders, Cardiovascular Diseases, Others)

      3. By End User (Hospitals & Clinics, Biopharmaceutical Companies, Research & Academic Institutes, Others)

      4. By Country

      5. By Company (2025)

    3. Product Map

  • United States RNA Therapeutics Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Type

      2. By Application

      3. By End User

  • Canada RNA Therapeutics Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Type

      2. By Application

      3. By End User

  • Mexico RNA Therapeutics Market Outlook

    1. Market Size & Forecast

      1. By Value

    2. Market Share & Forecast

      1. By Type

      2. By Application

      3. By End User

  • Market Dynamics

    1. Drivers

    2. Challenges

  • Market Trends & Developments

    1. Merger & Acquisition (If Any)

    2. Product Launches (If Any)

    3. Recent Developments

  • North America RNA Therapeutics Market: SWOT Analysis

  • Porter's Five Forces Analysis

    1. Competition in the Industry

    2. Potential of New Entrants

    3. Power of Suppliers

    4. Power of Customers

    5. Threat of Substitute Products

  • Competitive Landscape

    1. Moderna, Inc.

      1. Business Overview

      2. Products & Services

      3. Recent Developments

      4. Key Personnel

      5. SWOT Analysis

    2. BioNTech SE

    3. Alnylam Pharmaceuticals, Inc.

    4. Ionis Pharmaceuticals, Inc.

    5. Arrowhead Pharmaceuticals, Inc.

    6. Sarepta Therapeutics, Inc.

    7. Wave Life Sciences Ltd.

    8. Translate Bio, Inc. (Sanofi)

    9. Arcturus Therapeutics Holdings Inc.

    10. Dicerna Pharmaceuticals, Inc. (Novo Nordisk)

  • Strategic Recommendations

  • About Us & Disclaimer

    • Methodology